Depletion of host CD8+ and CD4+ T cells prior to treatment with the combination of a CD40 agonist and gemcitabine abrogated their efficacy on tumor growth [52], demonstrating a role for T cells in the therapeutic response. The gene discussed is CD8A; the disease is neoplasm.